Zymeworks ZWI-ZW171-101

{ "short_title": "Zymeworks ZWI-ZW171-101", "data_mode": "900", "data_mode_number": "000002385", "official_title": "A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": "NCT06523803", "eudract_number": "2024-511119-11", "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Diese Studie wird durchgef\u00fchrt, um herauszufinden, ob ZW171 sicher ist und Teilnehmer mit fortgeschrittenen (lokal fortgeschrittenen [inoperablen] und/oder metastasierten) Mesothelin-exprimierenden Krebsarten behandeln kann.", "description_laie_en": "This study is being conducted to find out if ZW171 is safe and can treat participants with advanced (locally advanced [inoperable] and/or metastatic) mesothelin-expressing cancers.", "description_expert_de": "Diese Studie wird durchgef\u00fchrt, um herauszufinden, ob ZW171 sicher ist und Teilnehmer mit fortgeschrittenen (lokal fortgeschrittenen [inoperablen] und/oder metastasierten) Mesothelin-exprimierenden Krebsarten behandeln kann.", "description_expert_en": "This study is being done to find out if ZW171 is safe and can treat participants withadvanced (locally advanced [inoperable] and/or metastatic) mesothelin-expressing cancers.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 10, "sub_cat_id": 50 }